No Data
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Alkermes Spinoff Mural Plunges on Plans to Halt Ovarian Cancer Trial
Axsome Therapeutics' Says FOCUS Phase 3 Trial Of Solriamfetol In The Treatment Of Attention Deficit Hyperactivity Disorder Achieved Its Primary And Key Secondary Endpoints Demonstrating Statistically Significant Improvements In Symptoms And Disease...
Crinetics Pharmaceuticals Analyst Ratings
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July
PTC Therapeutics Shares Are Trading Higher After the Company Announced Phase 3 APHENITY Trial Results.